	US 12,241,068 B2
	CD79-specific chimeric antigen receptor
Martin Pulé, London (GB); Shaun Cordoba, London (GB); Simon Thomas, London (GB); Shimobi Onuoha, London (GB); and Mathieu Ferrari, London (GB)
Assigned to AUTOLUS LIMITED, London (GB)
Appl. No. 17/055,387
Filed by AUTOLUS LIMITED, London (GB)
PCT Filed May 15, 2019, PCT No. PCT/GB2019/051331 § 371(c)(1), (2) Date Nov. 13, 2020, PCT Pub. No. WO2019/220110, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 1807870 (GB), filed on May 15, 2018.
Prior Publication US 2022/0273710 A1, Sep. 1, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01); A61K 38/00 (2006.01)

CPC C12N 15/625 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464411 (2023.05); A61K 39/464412 (2023.05); A61K 39/464413 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2239/13 (2023.05); A61K 2239/31 (2023.05); C12N 2740/10043 (2013.01)]

3 Claims

1. A chimeric antigen receptor (CAR) which specifically binds the unspliced portion of the CD79B ectodomain shown as SEQ ID NO: 146 and which comprises an antigen-binding domain comprising:

a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:

	(SEQ ID NO: 113)
	CDR1 - GFTFSNAA;

	(SEQ ID NO: 114)
	CDR2 - IRTKPNNYAT;

	(SEQ ID NO: 115)
	CDR3 - TYYDGSSYAMDA;

and

a light chain variable region (VL) having CDRs with the following sequences:

	(SEQ ID NO: 116)
	CDR1 - QSLEYSDGYTY;

	CDR2 - EVS;

	(SEQ ID NO: 117)
	CDR3 - FQATHDPYT;

b) a VH having CDRs with the following sequences:

	(SEQ ID NO: 121)
	CDR1 - GFTFSHTA;

	(SEQ ID NO: 122)
	CDR2 - IRIQPKNYAT;

	(SEQ ID NO: 123)
	CDR3 - TAAGFGFDY;

and